Fourpath Capital Management LLC Purchases Shares of 717 Insulet Corporation $PODD

Fourpath Capital Management LLC purchased a new stake in Insulet Corporation (NASDAQ:PODD) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 717 shares of the medical instruments supplier’s stock, valued at approximately $225,000.

Other hedge funds also recently modified their holdings of the company. Zions Bancorporation National Association UT acquired a new stake in shares of Insulet during the 1st quarter worth about $26,000. Larson Financial Group LLC lifted its stake in shares of Insulet by 426.3% during the 1st quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier’s stock worth $26,000 after buying an additional 81 shares during the last quarter. SouthState Corp lifted its stake in shares of Insulet by 253.3% during the 1st quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock worth $28,000 after buying an additional 76 shares during the last quarter. Kozak & Associates Inc. acquired a new stake in shares of Insulet during the 2nd quarter worth about $32,000. Finally, Ramirez Asset Management Inc. acquired a new stake in shares of Insulet during the 1st quarter worth about $53,000.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on PODD shares. Barclays raised their target price on shares of Insulet from $266.00 to $300.00 and gave the stock an “equal weight” rating in a research note on Thursday, August 21st. Rothschild & Co Redburn raised their target price on shares of Insulet from $350.00 to $370.00 and gave the stock a “buy” rating in a research note on Friday, October 3rd. Morgan Stanley reaffirmed an “overweight” rating on shares of Insulet in a research report on Thursday, August 7th. Piper Sandler raised their price target on shares of Insulet from $320.00 to $360.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 16th. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of Insulet in a research report on Thursday, August 7th. Seventeen analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, Insulet presently has a consensus rating of “Moderate Buy” and an average price target of $347.67.

Insulet Price Performance

Shares of NASDAQ:PODD opened at $314.52 on Friday. The firm has a 50 day moving average of $323.75 and a 200-day moving average of $300.12. The stock has a market capitalization of $22.14 billion, a PE ratio of 95.60, a PEG ratio of 2.66 and a beta of 1.40. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64. Insulet Corporation has a 12 month low of $226.50 and a 12 month high of $353.50.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, beating the consensus estimate of $0.92 by $0.25. The company had revenue of $649.10 million during the quarter, compared to analysts’ expectations of $612.31 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The business’s revenue for the quarter was up 32.9% compared to the same quarter last year. During the same period in the previous year, the company earned $0.55 EPS. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, equities research analysts predict that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Insider Activity at Insulet

In other news, SVP Laetitia Cousin sold 797 shares of the business’s stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the transaction, the senior vice president directly owned 3,890 shares in the company, valued at approximately $1,356,870.90. The trade was a 17.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Prem Singh sold 687 shares of the business’s stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the transaction, the senior vice president owned 3,456 shares of the company’s stock, valued at $1,200,925.44. The trade was a 16.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.39% of the stock is currently owned by insiders.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.